Comparative Pharmacology
Head-to-head clinical analysis: CONCERTA versus MYDAYIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONCERTA versus MYDAYIS.
CONCERTA vs MYDAYIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methylphenidate is a central nervous system (CNS) stimulant. It blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their levels in the synaptic cleft. It also acts as a dopamine agonist by stimulating the release of dopamine from storage sites.
MYDAYIS is a fixed-dose combination of amphetamine and dextroamphetamine, which are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mechanism of action in ADHD is not fully elucidated, but they block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase their release into the extraneuronal space.
18-72 mg orally once daily in the morning, starting at 18-36 mg/day and titrating in 18 mg increments weekly; maximum 72 mg/day.
Oral, 12.5 mg or 25 mg once daily in the morning.
None Documented
None Documented
Terminal elimination half-life of methylphenidate from CONCERTA is approximately 3.5 hours (range 2.5-5.5 hours) in adults; in children, mean half-life is 3-4 hours. The extended-release formulation provides a prolonged clinical effect due to the OROS delivery system, not prolonged half-life.
12 hours for d-methylphenidate; 3-4 hours for l-methylphenidate; clinical context: d-isomer provides extended coverage; l-isomer contributes minimal activity
Primarily renal (77%-87% as unchanged drug and metabolites); metabolic elimination accounts for 13%-23%, with minor biliary excretion (<2%).
Renal (approx. 90% as unchanged drug and 10% as inactive metabolites); fecal <5%
Category C
Category C
CNS Stimulant
CNS Stimulant